SCHEMBL240811

SCHEMBL240811

CCC1(COc2ccc(N)cc2)COC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.48
TSHR P16473 4/20 0.48
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 2/20 0.38
APP P05067 2/20 0.37
RAB9A P51151 3/20 0.36
MAOB P27338 3/20 0.36
GAA P10253 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36
MAOA P21397 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NFE2L2 Q16236 1/20 0.35
NPC1 O15118 2/20 0.34
TP53 P04637 1/20 0.34
NR4A1 P22736 1/20 0.33
LTA4H P09960 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12012112 0.94 TDP1 (0.46) TDP1TSHRMAPK1ALDH1A1CYP3A4
SCHEMBL36226 0.91 TSHR (0.40) TDP1TSHRMAPK1ALDH1A1LTA4H
SCHEMBL21089712 0.86 LTA4H (0.40) TSHRMAPK1ALDH1A1LTA4H
SCHEMBL36335 0.86 TSHR (0.37) TSHRMAPK1ALDH1A1CYP3A4RAB9A
SCHEMBL1127852 0.85 TSHR (0.39) TSHRALDH1A1CYP3A4GAAL3MBTL1
SCHEMBL13337534 0.84 FKBP1A (0.42) TSHRMAPK1ALDH1A1RAB9AL3MBTL1
SCHEMBL15334058 0.83 LTA4H (0.38) TSHRSMN1; SMN2L3MBTL1LTA4H
SCHEMBL21074919 0.83 APP (0.41) TSHRAPP
SCHEMBL10071618 0.83 TSHR (0.37) TDP1TSHRALDH1A1APPMAOB
SCHEMBL12227651 0.83 FKBP1A (0.41) TDP1TSHRALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
WO-2023113475-A1 POLYMER AND ORGANIC LIGHT-EMITTING DEVICE USING SAME 주식회사 엘지화학 2023-06-22 WO disclosed
WO-2020012601-A1 CHARGE-TRANSPORTING POLYMER AND ORGANIC ELECTRONICS ELEMENT 日立化成株式会社 2020-01-16 WO disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 US disclosed
US-20170157104-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
US-20170157105-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
EP-2678334-B1 ANTI-VIRAL COMPOUNDS ABBVIE BAHAMAS LTD (BS) 2017-03-22 EP disclosed
EP-2692726-A1 Anti-viral compounds Abbvie Inc. (US) 2014-02-05 EP disclosed
EP-2692346-A1 An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative Abbvie Inc. (US) 2014-02-05 EP disclosed
EP-2678334-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2014-01-01 EP disclosed
EP-2627651-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2013-08-21 EP disclosed
US-20120220562-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-08-30 US disclosed
WO-2012116257-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. (US) 2012-08-30 WO disclosed
WO-2012051361-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-19 WO disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 US disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 US disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885
US-20120220562-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885
US-20170157105-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885
US-20170157104-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS TDP1 3922/4885TSHR 4834/4885MAPK1 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.